TORONTO and OTTAWA, Feb. 18,
2016 /CNW/ - Bedrocan Canada Inc. ("Bedrocan Canada" or the
"Company") is pleased to announce the renewal of its license for
its main production facility in the Toronto area. In addition, re-asserting its
commitment to affordable medicine, Bedrocan Canada is also
announcing that its advocacy efforts to remove sales tax from
medical cannabis have advanced to the House of Commons where a
petition supporting the effort will be presented to Canada's lawmakers.
This is a promising step forward for a letter-writing campaign
that started less than a month ago respectfully asking the Hon.
Bill Morneau, Minister of Finance to
"zero-rate" medical cannabis, thereby removing sales tax from its
sale. Once achieved this change will remedy an unjust financial
burden on patients, and bring a viable treatment option in line
with the treatment of other prescription medicines.
Bedrocan Canada, a subsidiary of Canopy Growth Corporation
(TSX.V:CGC) is dedicated to advancing every aspect of medical
cannabis, from clinical research to physician education. As
Canada's cannabis laws evolve,
Bedrocan Canada will remain committed to improving the body or
knowledge, affordability and accessibility of medical cannabis.
"We are committed to advocating for patient issues, and ensuring
that the patient's voice does not get lost as a framework for
non-medical cannabis is established," said Bruce Linton, Chairman and CEO of Canopy
Growth. "Our commitment to affordability dates back to
May 2014 when we filed a request for
review of this rule by the Canada Revenue Agency. This latest
petition reflects our ongoing commitment to advance the issue of
affordability however we can."
Bedrocan Canada's advocacy for fair tax treatment of medical
cannabis follows closely on the introduction of True
Compassionate Pricing, a flat $5
price for all varieties and all customers.
We invite and encourage Canadians to visit
https://petitions.parl.gc.ca/en/Petition/Sign/e-190 to sign the
petition and join as a partner in driving this important message
forward.
About Bedrocan Canada
Bedrocan Canada is focused on medicinal cannabis production and
research, including, the EQUAL Study, which is currently enrolling
patients and evaluating how cannabis is affecting their quality of
life of Canadian patients. Bedrocan's standardized strains have
been used by tens of thousands of patients in seven countries
around the world. www.bedrocan.ca
About Canopy Growth Corporation
Canopy Growth is Canada's first publicly traded
medical marijuana company and the first geographically diversified
producer with multiple licenses under the Marihuana for Medical
Purposes Regulations. Through its wholly owned subsidiaries, Tweed,
Tweed Farms, and Bedrocan Canada, the Company operates three
state-of-the-art production facilities in Ontario and
distributes marijuana across the country to Canadian patients
managing a host of medical conditions. The Company is dedicated to
educating healthcare practitioners, providing consistent access to
high quality medication, conducting robust clinical research, and
furthering the public's understanding of how marijuana is used for
medical purposes. www.canopygrowth.com
Forward Looking Statement:
This news release contains forward-looking statements.
Often, but not always, forward-looking statements can be identified
by the use of words such as "plans", "expects" or "does not
expect", "is expected", "estimates", "intends", "anticipates" or
"does not anticipate", or "believes", or variations of such words
and phrases or state that certain actions, events or results "may",
"could", "would", "might" or "will" be taken, occur or be
achieved. Forward-looking statements involve known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company or any
of its subsidiaries to be materially different from any future
results, performance or achievements expressed or implied by the
forward-looking statements.
Although Canopy Growth Corp. has attempted to identify important
factors that could cause actual actions, events or results to
differ materially from those described in forward-looking
statements, there may be other factors that cause actions, events
or results not to be as anticipated, estimated or intended. Readers
should not place undue reliance on forward-looking statements. The
factors identified above are not intended to represent a complete
list of the factors that could affect the Company or any of its
subsidiaries. The forward-looking statements included in this news
release are made as of the date of this news release and Canopy
Growth Corp. does not undertake an obligation to publicly update
such forward-looking statements to reflect new information,
subsequent events or otherwise unless required by applicable
securities legislation.
SOURCE Canopy Growth Corporation